secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALPINE IMMUNE SCIENCES, INC. (—)
CIK:        0001626199
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001193125-24-091936
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex to acquire Alpine for $65/share (~$4.9B); deal expected to close Q2 2024
-------------------------------------------------------------------------------

- Total equity value ~$4.9B; Vertex will pay $65 per share in cash.
- Alpine’s lead drug povetacicept (dual BAFF/APRIL antagonist) showed best-in-class potential in IgA nephropathy; Phase 3 planned H2 2024.
- Stockholders owning ~25.5% of shares have agreed to tender; termination fee of $173M payable by Alpine under certain conditions.
- Transaction unanimously approved by both boards; expected to close in Q2 2024, subject to HSR and tender of majority of shares.
- Alpine’s pipeline includes studies in membranous nephropathy, lupus nephritis, and autoimmune cytopenias.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626199/000119312524091936/0001193125-24-091936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626199/000119312524091936/d820872d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-091936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer